GlassScriptPhysician profile
Myisha Anderson
NPI 1659027415
$673.80
in general payments reported to CMS, 2019-2025
13 companies · $81.07 in 2025
The $81.07 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $389 · 2024: $101 · 2025: $81.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $116.56 | 2022-2024 | Jornay Pm |
| Corium, LLC | $103.80 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $87.77 | 2023-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $65.96 | 2022-2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $52.27 | 2022-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.05 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $43.31 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $42.57 | 2022-2023 | Trintellix |
| Neuronetics, INC. | $33.48 | 2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $23.89 | 2023 | Aristada, Lybalvi |
| Abbvie INC. | $19.48 | 2023 | |
| Noven Therapeutics, LLC | $19.31 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $16.35 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myisha Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.